Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010

J Am Coll Cardiol. 2013 Aug 20;62(8):697-703. doi: 10.1016/j.jacc.2013.05.064. Epub 2013 Jun 27.

Abstract

Objectives: This study sought to characterize the prevalence of metabolic syndrome (MetS), its 5 components, and their pharmacological treatment in U.S. adults by sex and race/ethnicity over time.

Background: MetS is a constellation of clinical risk factors for cardiovascular disease, stroke, kidney disease, and type 2 diabetes mellitus.

Methods: Prevalence estimates were estimated in adults (≥ 20 years of age) from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2010 (in 2-year survey waves). The biological thresholds, defined by the 2009 Joint Scientific Statement, were: 1) waist circumference ≥ 102 cm (males adults) and ≥ 88 cm (female adults); 2) fasting plasma glucose ≥ 100 mg/dl; 3) blood pressure of ≥ 130/85 mm Hg; 4) triglycerides ≥ 150 mg/dl; and 5) high-density lipoprotein-cholesterol (HDL-C) <40 mg/dl (male adults) and <50 mg/dl (female adults). Prescription drug use was estimated for lipid-modifying agents, anti-hypertensives, and anti-hyperglycemic medications.

Results: From 1999 and 2000 to 2009 and 2010, the age-adjusted prevalence of MetS (based on biologic thresholds) decreased from 25.5% (95% confidence interval [CI]: 22.5% to 28.6%) to 22.9% (95% CI: 20.3% to 25.5%). During this period, hypertriglyceridemia prevalence decreased (33.5% to 24.3%), as did elevated blood pressure (32.3% to 24.0%). The prevalence of hyperglycemia increased (12.9% to 19.9%), as did elevated waist circumference (45.4% to 56.1%). These trends varied considerably by sex and race/ethnicity. Decreases in elevated blood pressure, suboptimal triglycerides, and high-density lipoprotein-cholesterol prevalence have corresponded with increases in anti-hypertensive and lipid-modifying drugs, respectively.

Conclusions: The increasing prevalence of abdominal obesity, particularly among female adults, highlights the urgency of addressing abdominal obesity as a healthcare priority. The use of therapies for MetS components aligns with favorable trends in their prevalence.

Keywords: CI; CVD; HDL-C; MA; MetS; Mexican-American; NHANES; National Health and Nutrition Examination Survey; T2DM; cardiovascular disease; confidence interval; high-density lipoprotein cholesterol; hypertension; hypertriglyceridemia; metabolic syndrome; metabolic syndrome; type II diabetes mellitus; waist circumference.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Blood Pressure
  • Cardiovascular Diseases / epidemiology
  • Cholesterol, HDL / blood
  • Diabetes Mellitus, Type 2 / epidemiology
  • Humans
  • Kidney Diseases / epidemiology
  • Metabolic Syndrome / drug therapy
  • Metabolic Syndrome / epidemiology*
  • Obesity, Abdominal / epidemiology
  • Prevalence
  • Risk Factors
  • Stroke / epidemiology
  • Triglycerides / blood
  • United States / epidemiology

Substances

  • Cholesterol, HDL
  • Triglycerides